Shanghai, China - Jiaoze CDMO Services, a leading global contract pharmaceutical manufacturing and development organization, today announced a major expansion of its manufacturing facilities to meet growing global drug development and manufacturing needs. This strategic expansion is expected to significantly enhance the company's manufacturing capabilities and accelerate the market launch of new pharmaceutical products.
With the rapid development of the global pharmaceutical industry, the demand for CDMO services is rising. Jiaoze CDMO Services occupies an important position in the field of contract manufacturing and drug development services with its advanced technology platform and professional service team. The company provides a full range of services from drug discovery, clinical trial material production to commercial production, helping its partners accelerate the drug development process.
The expansion plan includes the addition of multiple production lines, the introduction of the latest bioreactor technology, and the expansion of analytical laboratories and quality control centers. This will enable Jiaoze CDMO Services to more efficiently meet diverse drug production needs, including biopharmaceuticals and small molecule drugs. The new facility is expected to be completed within the next two years and will create hundreds of highly skilled jobs.
CEO of Jiaoze CDMO Services said in a press release: "We are very excited about being able to expand our service capabilities and further support our customers around the world in their drug development journeys. This expansion is not only a commitment to our continued growth; Demonstrating commitment to our customers and patients. With this expansion, we will be able to provide more efficient and flexible services to respond to rapidly changing market needs."
Jiaoze CDMO Services’ expansion plan has been widely recognized by industry experts. Many industry analysts believe that this move will further consolidate Jiaoze's leading position in the global CDMO market and help drive the entire industry to develop in a more efficient and innovative direction.
With the new facility operational, Jiaoze CDMO Services expects to be able to provide its customers with faster, higher-quality products while also bringing more treatment options to patients around the world. The successful implementation of this expansion project will undoubtedly bring new growth opportunities to Jiaoze CDMO Services, while also contributing to the stability and innovation of the global drug supply chain.
About Jiaoze CDMO Services:
Jiaoze CDMO Services is a global company that provides comprehensive drug development and manufacturing services, including drug discovery, formulation development, preclinical and clinical-stage drug manufacturing, and commercial manufacturing. The company is committed to helping its partners accelerate the drug launch process and benefit patients by providing high-quality and efficient one-stop services.
